We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Medarex and Xerion to Collaborate on Antibody Products

By Biotechdaily staff writers
Posted on 30 Jan 2004
An agreement under which the two companies plan to develop fully human therapeutic antibody products has been announced by Xerion Pharmaceuticals AG (Munich, Germany) and Medarex, Inc. More...
(Princeton, NJ, USA).

Under the terms of the contract, Xerion plans to contribute disease-associated targets identified through it Xstream technology, while Medarex expects to generate fully human antibody product candidates against these targets using its UltiMAb Human Antibody Development System. Both companies agree to share equally the costs and responsibilities of resulting product development and intend to jointly commercialize any antibody products resulting from this collaboration.

"We believe that the combination of Xerion's Xstream platform and our UltiMAb technology has the potential to result in novel therapeutics, and we look forward to working with Xerion in this endeavor,” said Donald L. Drakeman, president and CEO of Medarex.

Xerion >> www.xerion-pharma.com
Medarex >> www.medarex.co
(Princeton, NJ, USA; www.medarex.com).

Under the terms of the contract, Xerion plans to contribute disease-associated targets identified through it Xstream technology, while Medarex expects to generate fully human antibody product candidates against these targets using its UltiMAb Human Antibody Development System. Both companies agree to share equally the costs and responsibilities of resulting product development and intend to jointly commercialize any antibody products resulting from this collaboration.

"We believe that the combination of Xerion's Xstream platform and our UltiMAb technology has the potential to result in novel therapeutics, and we look forward to working with Xerion in this endeavor,” said Donald L. Drakeman, president and CEO of Medarex.




Related Links:
Xerion
Medarex

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.